The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Por:
Vazquez, JC, Pinero, A, de Castro, FJ, Lluch, A, Martin, M, Barnadas, A, Alba, E, Rodriguez-Lescure, A, Rojo, F, Gimenez, J, Sola, I, Quintana, MJ, Bonfill, X, Urrutia, G, Sanchez-Rovira, P
Publicada:
1 ene 2023
Ahead of Print:
1 sep 2022
Resumen:
Purpose To conduct a systematic review to analyse the performance of the sentinel lymph-node biopsy (SLNB) in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy, compared to axillary lymph-node dissection. Methods The more relevant databases were searched. Main outcomes were false-negative rate (FNR), sentinel lymph-node identification rate (SLNIR), negative predictive value (NPV), and accuracy. We conducted meta-analyses when appropriate. Results Twenty studies were included. The pooled FNR was 0.14 (95% CI 0.11-0.17), the pooled SLNIR was 0.89 (95% CI 0.86-0.92), NPV was 0.83 (95% CI 0.79-0.87), and summary accuracy was 0.92 (95% CI 0.90-0.94). SLNB performed better when more than one node was removed and double mapping was used. Conclusions SLNB can be performed in women with a node-negative tumour after neoadjuvant therapy. It has a better performance when used with previous marking of the affected node and with double tracer.
Filiaciones:
Vazquez, JC:
Biomed Res Inst St Pau IIB St Pau, Iberoamer Cochrane Ctr, Barcelona, Spain
Pinero, A:
Hosp Clin Univ Virgen de la Arrixaca, GEICAM Spanish Breast Canc Grp, Murcia, Spain
de Castro, FJ:
GEICAM Spanish Breast Canc Grp, Complejo Asistencial Salamanca, Salamanca, Spain
Lluch, A:
Univ Valencia, Hosp Clin Univ Valencia, Ctr Invest Biomed Red Oncol,GEICAM Spanish Breast, Biomed Res Inst INCLIVA,Med Oncol Unit,CIBERONC I, Valencia, Spain
Martin, M:
Univ Complutense Madrid, Ctr Invest Biomed Red Oncol, Inst Invest Sanitaria Gregorio Maranon, GEICAM Spanish Breast Canc Grp,CIBERONC ISCIII,GE, Madrid, Spain
Barnadas, A:
Hosp La Santa Creu & St Pau, Med Oncol Unit, GEICAM Spanish Breast Canc Grp, Ctr Invest Biomed Red Oncol,CIBERONC ISCIII, Barcelona, Spain
Alba, E:
Hosp Reg & Virgen de la Victoria, Ctr Invest Biomed Red Oncol, CIBERONC ISCIII, IBIMA,GEICAM Spanish Breast Canc Grp,UGCI Oncol M, Malaga, Spain
Rodriguez-Lescure, A:
Hosp Gen Univ Elche, GEICAM Spanish Breast Canc Grp, Alicante, Spain
Rojo, F:
Hosp Univ Fdn Jimenez Diaz, Ctr Invest Biomed Red Oncol, CIBERONC ISCIII, GEICAM Spanish Breast Canc Grp, Madrid, Spain
Gimenez, J:
Inst Valenciano Oncol IVO, GEICAM Spanish Breast Canc Grp, Valencia, Spain
Sola, I:
CIBER Epidemiol & Salud Publ CIBERESP, Iberoamer Cochrane Ctr, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Quintana, MJ:
Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, CIBER Epidemiol & Salud Publ CIBERESP, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Bonfill, X:
Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, CIBER Epidemiol & Salud Publ CIBERESP, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Urrutia, G:
Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, CIBER Epidemiol & Salud Publ CIBERESP, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Sanchez-Rovira, P:
Complejo Hosp Jaen, Med Oncol Unit, GEICAM Spanish Breast Canc Grp, Jaen, Spain
|